|
29/10/2024
|
07:00
|
Q3 Trading Update
|
RNS
|
|
25/09/2024
|
07:00
|
Results from Phase 3 paediatric study
|
RNS
|
|
04/09/2024
|
07:00
|
Interim results
|
RNS
|
|
27/08/2024
|
07:00
|
ACCRUFeR® Approved by Health Canada
|
RNS
|
|
14/08/2024
|
07:00
|
Notice of interim results
|
RNS
|
|
24/07/2024
|
07:01
|
Unaudited Q2 2024 Trading Update
|
RNS
|
|
24/07/2024
|
07:00
|
Directorate Change
|
RNS
|
|
03/07/2024
|
07:00
|
$5.7m Milestone Monetization Agreement with AOP
|
RNS
|
|
20/06/2024
|
16:25
|
Results of 2024 Annual General Meeting
|
RNS
|
|
28/05/2024
|
07:00
|
New Drug Application for Accrufer® in South Korea
|
RNS
|
|
10/05/2024
|
15:30
|
Audited results for the year ended 31 Dec 2023
|
RNS
|
|
30/04/2024
|
07:00
|
Business Update for Q1 2024
|
RNS
|
|
16/04/2024
|
07:00
|
Notice of Results
|
RNS
|
|
21/02/2024
|
07:00
|
Unaudited Full Year Trading Update
|
RNS
|
|
09/01/2024
|
07:00
|
Appointment of new Chief Financial Officer
|
RNS
|
|
07/12/2023
|
07:00
|
Q3 2023 U.S. Commercial Highlights
|
RNS
|
|
27/11/2023
|
17:24
|
PDMR Transaction Notification
|
RNS
|
|
15/11/2023
|
07:30
|
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
|
EQS Group
|
|
12/10/2023
|
07:00
|
Chief Financial Officer Transition
|
RNS
|
|
03/10/2023
|
15:00
|
Result of REX Retail Offer
|
RNS
|
|
03/10/2023
|
07:00
|
Completion of SWK Financing
|
RNS
|
|
03/10/2023
|
07:00
|
Block listing Interim Return
|
RNS
|
|
28/09/2023
|
12:50
|
Successful completion of US$6.1m Equity Fundraise
|
RNS
|
|
28/09/2023
|
07:02
|
REX Retail Offer
|
RNS
|
|
28/09/2023
|
07:01
|
$20m secured debt facility &proposed equity raise
|
RNS
|
|
28/09/2023
|
07:00
|
Interim results update and business update
|
RNS
|
|
06/09/2023
|
07:00
|
Notice of Results and Change in reporting currency
|
RNS
|
|
25/07/2023
|
09:45
|
Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
|
EQS Group
|
|
24/07/2023
|
14:27
|
Holding(s) in Company
|
RNS
|
|
20/07/2023
|
07:00
|
Business Update and U.S. Q2 2023 Highlights
|
RNS
|
|
28/06/2023
|
17:30
|
Results of 2023 Annual General Meeting
|
RNS
|
|
16/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
15/06/2023
|
16:35
|
Lapse of Offer
|
RNS
|
|
15/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
15/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
14/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
14/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
13/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
13/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
12/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
12/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
09/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
09/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
08/06/2023
|
12:31
|
Form 8.3 - Shield Therapeutics PLC (amendment)
|
RNS
|
|
08/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
08/06/2023
|
07:00
|
Acceptance Level Update
|
RNS
|
|
07/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
06/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|
|
06/06/2023
|
10:10
|
Grant of share options to the CEO
|
RNS
|
|
05/06/2023
|
12:00
|
Form 8.5 (EPT/RI) - Shield Therapeutics Plc
|
RNS
|